Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Shingrix (Zostavax) Market Growth Potential: How Will Market Size Change Through 2030?
The rise observed in the historic period resulted from greater public understanding of shingles-related complications, a worldwide increase in the elderly population, earlier constraints associated with live attenuated vaccines, broader vaccination recommendations targeted at older adults, and a growing frequency of healthcare provider endorsements.
The expansion anticipated during the forecast period is driven by heightened targets for adult vaccination coverage, greater healthcare expenditure on preventive measures, an expanding pipeline of recombinant vaccines, the proliferation of government-backed immunization campaigns, and a growing effort to alleviate the burden of post-herpetic neuralgia. Key developments expected in this period involve the widespread utilization of recombinant vaccine technologies, a stronger emphasis on adult immunization schedules, increasing consumer demand for durable protection against shingles, broader implementation of cold-chain-efficient vaccine logistics, and a reinforced focus on ensuring vaccine safety and efficacy.
Download A Free Sample Report For Comprehensive Market Insights:
Shingrix (Zostavax) Market Development Factors: Which Trends Are Supporting Demand?
The rising uptake of vaccination is anticipated to drive forward the expansion of the shingrix (zostavax) market in the coming period. Vaccination involves delivering a vaccine to activate the immune system, enabling it to identify and combat particular pathogens. This increasing trend is fueled by heightened awareness of vaccination’s effectiveness in illness prevention, reduction of disease impact, and the creation of safe, accessible vaccines. Widespread acceptance is further supported by public health campaigns, enhanced healthcare systems, and global immunization efforts. Shingrix (Zostavax) plays a key role in vaccination by offering robust defense against shingles and its associated risks, especially for adults aged 50 and over, markedly lowering the chance of shingles return and post-herpetic neuralgia. For example, a May 2024 study in the Journal of the American Medical Association (JAMA), a US-based peer-reviewed journal, reported that shingles vaccinations covered by Medicare Part D rose by 46% in the year following the IRA policy’s start in January 2023. Consequently, the growing adoption of vaccination is fueling growth in the shingrix (zostavax) market.
Shingrix (Zostavax) Market Categorization By Product Type And Application
The shingrix (zostavax) market covered in this report is segmented –
1) By Formulation: Recombinant Vaccine (Shingrix), Live Attenuated Vaccine (Zostavax)
2) By Indication: Shingles Prevention, Post-Herpetic Neuralgia
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy
Shingrix (Zostavax) Market Transformation Trends: Which Innovations Are Driving Change?
Key players in the shingrix (zostavax) market are concentrating on advancing novel approaches, such as non-live, recombinant subunit adjuvanted vaccines, to address the growing need for safer and more effective immunization, fueled by age-associated immune decline and the requirement for options among immunocompromised individuals. A non-live, recombinant subunit adjuvanted vaccine consists of specific protein components (antigens) from a pathogen, paired with an adjuvant to enhance immune responses, in contrast to traditional live-attenuated vaccines that rely on weakened whole viruses. For example, in 2023, GSK plc, a biopharmaceutical company based in the United Kingdom, introduced Shingrix (Recombinant Zoster Vaccine, RZV) in India. This vaccine is non-live, administered intramuscularly in two doses, and features the glycoprotein E antigen combined with GSK’s proprietary AS01B adjuvant system. Shingrix produces a robust and sustained immune response, counteracting immunity waning in older adults, and demonstrates exceptional efficacy, reaching up to approximately 97%.
Shingrix (Zostavax) Market Company Landscape And Strategic Competition
Major companies operating in the shingrix (zostavax) market are GSK plc
Access The Complete Shingrix (Zostavax) Market Report:
Shingrix (Zostavax) Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the shingrix (zostavax) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model